ClinicalTrials.gg
RecruitingNCT04671212Updated Nov 3, 2026

Discarded Bone Marrow for Hematology Research

An observational study in Hemoglobinopathies, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by St. Jude Children's Research Hospital · Observational

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Hemoglobinopathies with a site in United States — 17 open to participants now, 27 under way, 5 of them phase 3. Hemoglobinopathies · United States.

Planned enrollment
9th of 13
50 · median 67
Started
2022
with 7 others
Observational
13 of 58
6 open now
Primary completion
2030-01
later than 17 of 26 live
Registered
42nd of 58
by date

Among the 58 studies in Hemoglobinopathies with a site in United States, this one is the 9th largest by planned enrollment of the 13 observational ones that give a count, is one of 8 that started in 2022, is one of 13 observational ones, reaches primary completion later than 17 of the 26 other live ones, and was the 42nd registered.

Hemoglobinopathies

100 studies on the registry are indexed under Hemoglobinopathies; 29 are open to participants now.

Browse Hemoglobinopathies studies →

Open to participants now

17 of the 58 studies in Hemoglobinopathies with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Hemoglobinopathies studies recruiting now, 7 (29%) set no upper age limit and 14 (58%) stop at 75 or younger; 20 take children under 18; 3 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Hemoglobinopathies with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to establish a mechanism to obtain discarded bone marrow-containing bone samples from hemoglobinopathy, as well as non-hemoglobinopathy individuals. The processing of samples will help to understand how best to manipulate HSPC's from hemoglobinopathy patients with gene therapy and gene technologies in the laboratory environment. It will also allow us to establish a reservoir of samples that can be studied in the future to assess cellular function and fitness for transplant.

Secondary objectives

  • To develop gene transfer and gene editing strategies as potentially curative therapy for hemoglobinopathies (e.g. sickle cell disease (SCD) and β-thalassemia).
  • To develop a drug treatment strategy which elevates the expression of fetal hemoglobin to a potentially curative level for hemoglobinopathies.
  • To examine the biology of bone marrow cells isolated from patients with hemoglobinopathies.
Read the detailed description

The hemoglobinopathies (e.g. sickle cell disease (SCD) and thalassemia) are devastating inherited anemias that shorten and reduce quality of life. The only current curative therapy for SCD is bone marrow transplantation. However, many patients lack access to suitable donors for transplant. Alternative treatments based on gene therapy, gene editing and novel drugs are currently being developed and show great promise for hemoglobinopathies. Gene therapy and gene editing are especially appealing because they eliminate both the need for donors and the potentially devastating side effects of Graft-versus-Host Disease because they take advantage of the patients own cells. In gene therapy approaches, hematopoietic stem and progenitor cells (HSPCs) are collected from a patient and then treated to 'correct' or 'replace' the disease-causing mutation. However, much work remains to develop optimal gene therapy and gene editing protocols, as well as better understand the inherent biology of HSPCs in patients with hemoglobinopathies.

Researchers at St. Jude want to learn how to best manipulate HSPCs from hemoglobinopathy patients with gene therapy and gene editing technologies to achieve optimal gene correction and/or replacement, as well as optimal engraftment of 'corrected' HSPCs after transplantation. St. Jude researchers also seek to test candidate drugs on SCD HSPCs that might ameliorate the symptoms of SCD. Finally, St. Jude researchers seek to thoroughly characterize the basic biology and function of HSPCs isolated from hemoglobinopathy patients.

Bone marrow-containing bone samples that are typically discarded during orthopedic surgery will be saved from hemoglobinopathy patients, as well as non- hemoglobinopathy patients, undergoing these surgeries. These samples will be shipped to the St. Jude Hematology Department for experimental research aimed at addressing the primary and secondary objectives of this protocol.

03

Conditions studied

  • Hemoglobinopathies

Browse trials for

Keywords

  • Bone samples
  • Bone marrow
  • Discarded
  • Hemoglobinopathies
  • Non-hemoglobinopathies
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants who meet the Eligibility Criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of any age receiving orthopedic surgery for clinical management that involve bone marrow containing bone discard.
  • Patients receiving orthopedic surgery for clinical management will be considered for this study if they have the following diagnosis and criteria:

    • Homozygous S/S disease or doubly heterozygous for S and β thalassemia who are two years or older are eligible.
    • HbE-β- thalassemia or homozygous (severe) β-thalassemia. including those who are transfusion dependent (major) or severely anemic but relatively transfusion independent (intermedia). Diagnostic criteria include standard hematological parameters, red cell indices, electrophoresis and quantitative determination of HbF and HbA2.

Exclusion criteria

Exclusion Criteria:

  • Active, acute manifestations of sickle cell disease including painful crisis, acute chest syndrome, cerebrovascular events or active infection.
  • Pregnant women will not be eligible for study enrollment
  • Inability or unwillingness of the research participant or legal guardian/representative to give written will preclude enrollment on this research protocol.
  • count \< 150,000/mm\^3
  • \< 2000/mm\^3
  • Neutrophil count \< 1000/mm\^3 for patients on hydroxyurea therapy
  • > 17 seconds
  • Partial thromboplastin Time > 43 seconds
  • History of excessive bleeding in the context of previous procedures including surgery and dental extractions
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Orthopedic Surgery Patients

    Participants receiving orthopedic surgery for clinical management that involve bone marrow containing bone discard.

06

What researchers measure

Primary outcomes

  1. Collection, processing and storage of discarded bone marrow-containing bone samples from hemoglobinopathy, as well as non-hemoglobinopathy individuals.

    Discarded bone marrow-containing bone samples will be collected for use in research; The processing of samples will help to understand how best to manipulate HSPC's from hemoglobinopathy patients with gene therapy and gene technologies in the laboratory environment. It will also allow us to establish a reservoir of samples that can be studied in the future to assess cellular function and fitness for transplant. Samples may be subject to comprehensive assessment of hematopoietic activity using tissue culture based assays, as well as molecular profiling studies of global transcriptome and epigenomes.

    Time frame: After completion of sample collection, approximately 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jan 2030, 90 months after the start.

Of 21 observational studies under Hemoglobinopathies, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 68. This study's planned 90 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2020
First posted
Dec 17, 2020
StartActual
Jul 26, 2022
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2035
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04671212
Responsible party
Sponsor
First posted
Dec 17, 2020
Start date
Jul 26, 2022
Primary completion
Jan 2030 (estimated)
Completion
Jan 2035 (estimated)
Last update
Nov 3, 2026

Study contacts

Shannon McKinney-Freeman, Ph.D.
Contact
referralinfo@stjude.org
888-226-4343
Shannon McKinney-Freeman, Ph.D.
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion